In fact, a phase II clinical trial showed Bortezomib, a NF-κB signaling inhibitor, to be well tolerated with an overall response rate of 67% in individuals with relapsed or refractory CTCL (128). This evidence concerns the gene NFKB1 and primary cutaneous T-cell non-Hodgkin lymphoma.